Organization | Yake Biotechnology Ltd.

Yake Biotechnology Ltd. Report issue

Government Phase 1 Phase 2

Organization Overview

First Clinical Trial

2018

NCT04283006

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Shanghai YaKe Biotechnology Ltd. | Yake Biotechnology Ltd.

Active Ingredients

Drugs in Phase 2 Trials (6)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

april-baff-bicephali car-t cells (1 trial)

bcma-pd1-cart cell (2 trials)

cd19 car-t cells (6 trials)

cd22 car-t cells (2 trials)

cd7 car-t cell (4 trials)

Drugs in Phase 1 Trials (17)

april car-t cells (1 trial)

autologous hematopoietic stem cells (1 trial)

bcma/cd19 dual-target car-t (6 trials)

cd20/cd22 targeted car t-cells (1 trial)

cd38 car-t cells (1 trial)

cd70 car-t cells (1 trial)

cd79b car-t cells (1 trial)

ciltacabtagene autoleucel (Carvykti) (2 trials)

cll-1.car t cells (1 trial)

cs1 car-t cell (1 trial)

cyclophosphamide (cytoxan) (1 trial)

deeptag-gprc5d targeted car t-cells (1 trial)

fludarabine (fludara) (1 trial)

il3 car-t cells (1 trial)

lmp1 car t-cells (1 trial)

murine cd19 car-t cells (1 trial)

nkg2d car-t cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hematologic Neoplasms (Phase 2)

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Recurrence (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 33
# of Trial APIs: 23